Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum type A2 toxin - Shionogi

Drug Profile

Botulinum type A2 toxin - Shionogi

Alternative Names: 150kDa botulinum type A toxin - KM Biologics; A2NTX; Botulinum type A toxin (150kDa) - KM Biologics; LMW botulinum type A toxin; Low molecular weight botulinum type A toxin; NTX

Latest Information Update: 06 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaketsuken; University of Tokushima
  • Developer Kaketsuken; Shionogi; University of Tokushima
  • Class Analgesics; Anti-inflammatories; Antidepressants; Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Skin disorder therapies; Urologics
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Muscle spasticity
  • Discontinued Dystonia

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for clinical-Phase-Unknown development in Muscle-spasticity in Japan (Intradermal, Injection)
  • 11 Dec 2017 Discontinued - Clinical-Phase-Unknown for Dystonia in Japan (Intradermal) (Kaketsuken pipeline, December 2017)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top